

Clinical Trial Studies Ways to Reduce Progression of Diabetic Neuropathy


PROBLEM

Your patients suffer from pain and numbness in their feet associated with diabetes.

SOLUTION

Clinical trial underway for preventing progression of diabetic neuropathy.

Dr. David Olson



Over 10 percent of the United States adult population has impaired glucose control. This impairment leads to an abnormal deposition of glucose-related molecules into the nerves and tissues of the body. Diabetic neuropathy is a slowly progressive deterioration of the nerves, which leads to burning pain and numbness. Over time this leads to impaired ability to walk and affects balance.

Drs. David Olson, Joshua Turknett, and Marshall Nash are currently enrolling patients in a clinical research trial of Ranirestat. This drug taken in oral form (versus placebo) is an aldose reductase inhibitor, which blocks deposition of sorbitol into the nerves. The study is to determine whether this will prevent the progression of diabetic neuropathy in patients who receive the drug. Patients are followed with a series of nerve conduction studies to document the extent of progression or reversal of nerve damage.

The screening evaluation includes a laboratory evaluation for alternative causes of neuropathy and the nerve conduction study at no charge to your patients or their insurance company. Patients who do not qualify are eligible to screen for several other clinical trials designed to find medicines that reduce the pain symptoms of this disease.

For more information, call DeKalb Neurology Associates, LLC at **404.508.4008**.